NASDAQ:CMMB Chemomab Therapeutics (CMMB) Stock Price, News & Analysis $1.03 -0.05 (-4.63%) Closing price 10/23/2026 03:56 PM EasternExtended Trading$1.03 0.00 (0.00%) As of 10/23/2026 06:17 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOwnershipSEC Filings About Chemomab Therapeutics Stock (NASDAQ:CMMB) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Chemomab Therapeutics alerts:Sign Up Key Stats Today's Range$1.01▼$1.2150-Day Range$1.03▼$2.8352-Week Range$1.01▼$3.44Volume25,886 shsAverage Volume109,397 shsMarket Capitalization$7.47 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingReduce Company Overview Chemomab Therapeutics Ltd. is a clinical-stage biotechnology company focused on developing therapies for chronic inflammatory and fibrotic diseases. The company’s research is centered on CCL24, a chemokine believed to contribute to inflammation, fibrosis and tissue damage across several disease areas. Chemomab’s lead product candidate is CM-101, a proprietary monoclonal antibody designed to block CCL24 activity. The therapy has been evaluated in clinical studies for conditions including primary sclerosing cholangitis, a progressive liver disease, and systemic sclerosis, an autoimmune disorder that can cause widespread fibrosis. CM-101 remains an investigational product and has not been approved for commercial use. Founded in Israel, Chemomab operates as an international biotechnology company serving the global biopharmaceutical and clinical research markets. The company is led by Chief Executive Officer Dr. Adi Zuloff-Shani and is listed on the Nasdaq Capital Market under the symbol CMMB.AI Generated. May Contain Errors. Read More Chemomab Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks24th Percentile Overall ScoreCMMB MarketRank™: 1.192856190855 of 5 starsChemomab Therapeutics scored higher than 24% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion1.0 / 5Analyst RatingReduce Consensus RatingChemomab Therapeutics has received a consensus rating of Reduce. The company's average rating score is 1.50, and is based on no strong buy ratings, no buy ratings, 1 hold rating, and 1 sell rating.Amount of Analyst CoverageChemomab Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about Chemomab Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Chemomab Therapeutics is -0.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Chemomab Therapeutics is -0.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioChemomab Therapeutics has a P/B Ratio of 0.52. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Chemomab Therapeutics' valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.17% of the float of Chemomab Therapeutics has been sold short.Short Interest Ratio / Days to CoverChemomab Therapeutics has a short interest ratio ("days to cover") of 0.05, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Chemomab Therapeutics has recently decreased by 87.13%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldChemomab Therapeutics does not currently pay a dividend.Dividend GrowthChemomab Therapeutics does not have a long track record of dividend growth. News and Social MediaN/ANews SentimentN/A Company Ownership1.7 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Chemomab Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $6,516.00 in company stock.Percentage Held by Insiders11.91% of the stock of Chemomab Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions46.05% of the stock of Chemomab Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Chemomab Therapeutics' insider trading history. Receive CMMB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Chemomab Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CMMB Stock News HeadlinesChemomab Therapeutics to Present at H.C. Wainwright 28th Annual Global Investor ConferenceAugust 31, 2026 | globenewswire.comChemomab Therapeutics Ltd.: Chemomab Therapeutics Announces Second Quarter 2026 Financial Results and Provides Corporate UpdateAugust 19, 2026 | finanznachrichten.deLast call for your free 0DTE reportThe 0DTE Game Plan lays out a simple 3-step framework for trading same-day options: Plan it, profit from it, protect it. This report normally sells for 29.97, but it's available as a free download for a limited time.October 24 at 1:00 AM | Profits Run (Ad)Chemomab Therapeutics Announces Second Quarter 2026 Financial Results and Provides Corporate UpdateAugust 19, 2026 | globenewswire.comChemomab Therapeutics Ltd. (CMMB) M&A Call Prepared Remarks TranscriptJuly 8, 2026 | seekingalpha.comChemomab to merge with Scipher MedicineJuly 8, 2026 | msn.comChemomab Therapeutics and Precision Medicine Pioneer Scipher Medicine Announce Merger Agreement to Advance Nebokitug in an AI-Powered Phase 2 Trial in Rheumatoid ArthritisJuly 8, 2026 | globenewswire.comChemomab Therapeutics Stock Short Interest Report | NASDAQ:CMMB | BenzingaJuly 7, 2026 | benzinga.comSee More Headlines CMMB Stock Analysis - Frequently Asked Questions How have CMMB shares performed this year? Chemomab Therapeutics' stock was trading at $1.65 on January 1st, 2026. Since then, CMMB stock has decreased by 37.6% and is now trading at $1.03. How were Chemomab Therapeutics' earnings last quarter? Chemomab Therapeutics Ltd. Sponsored ADR (NASDAQ:CMMB) issued its quarterly earnings data on Thursday, August, 20th. The company reported ($0.27) EPS for the quarter, missing the consensus estimate of ($0.15) by $0.12. When did Chemomab Therapeutics' stock split? Shares of Chemomab Therapeutics reverse split on the morning of Tuesday, August 26th 2025.A 1-4 reverse split was announced. The number of shares owned by shareholders was adjusted after the market closes on Monday, August 25th 2025. An investor that had 100 shares of stock prior to the reverse split would have 25 shares after the split. When did Chemomab Therapeutics IPO? Chemomab Therapeutics (CMMB) raised $31 million in an initial public offering on Tuesday, February 12th 2019. The company issued 2,652,174 shares at $11.50 per share. How do I buy shares of Chemomab Therapeutics? Shares of CMMB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Chemomab Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Chemomab Therapeutics investors own include Palantir Technologies (PLTR), Alibaba Group (BABA), Butterfly Network (BFLY), AbCellera Biologics (ABCL), Bridgeline Digital (BLIN), Bit Digital (BTBT) and CrowdStrike (CRWD). Company Calendar Last Earnings8/20/2026Today10/24/2026Next Earnings (Estimated)11/06/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (3w+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 For the last 3 weeks, CMMB's financial health has been in the Yellow zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:CMMB CIK1534248 Webwww.chemomab.com Phone972-77-331-0156FaxN/AEmployees12Year Founded2010Profitability EPS (Trailing Twelve Months)($2.13) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$8.99 million Net MarginsN/A Pretax MarginN/A Return on Equity-92.14% Return on Assets-82.05% Debt Debt-to-Equity RatioN/A Current Ratio6.41 Quick Ratio6.41 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.00 per share Price / Book0.52Miscellaneous Outstanding Shares7,250,000Free Float6,383,000Market Cap$7.47 million OptionableNot Optionable Beta0.74 7 Blue-Chip Stocks to Add To Your Forever PortfolioA strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership. This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.Get This Free Report This page (NASDAQ:CMMB) was last updated on 10/23/2026 by MarketBeat.com Staff. From Our PartnersHow I’m playing the AI melt-up (and down)Porter Stansberry says a powerful new market shift is forming and most investors are missing it entirely. I...Porter & Company | SponsoredFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American financial crashes over his 55-year career leadin...Weiss Ratings | SponsoredElon Musk’s One Stock Retirement PlanStanley Druckenmiller once said you don't get rich diversifying into 50 mediocre assets - you get rich finding...Brownstone Research | SponsoredIf you keep cash in a U.S. bank account… read this NOWSince 2020, U.S. banks have been required to keep zero percent of deposits on hand, lending out nearly every d...Banyan Hill Publishing | SponsoredThis free guide explains options the way they should be taughtMost options educators jump straight into Greeks, spreads, and implied volatility - losing beginners before th...Base Camp Trading | Sponsored$29.97 or $0 todayThe 0DTE Game Plan normally sells for 29.97, but it is free today through this link. Inside is a straightfo...Profits Run | SponsoredYour book is insideBlane Markham and the Markham Trading Team are giving readers a limited window to download their options strat...TradeWins | SponsoredI'm giving you a space stock today. Free.On December 8th, $600 billion in frozen SpaceX stock comes loose. Dylan Jovine says one simple purchase in any...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Chemomab Therapeutics Ltd. Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Chemomab Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
